Basal-like breast cancers

Pathology Case Reviews

Volumn 12, Issue 4, 2007, Pages 143-153

  Fadare, Oluwole ^a   Yeh, I Tien ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Basal like; Basal type; Breast; Carcinoma; Gene expression profiling; Pathology

Indexed keywords

CAVEOLIN 1; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P63; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR GATA 3;

ADULT; BREAST CANCER; BREAST SURGERY; CASE REPORT; CHROMOSOME; CHROMOSOME 10P; CHROMOSOME 16Q; CHROMOSOME 1Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME 9P; CLUSTER ANALYSIS; DISEASE FREE SURVIVAL; DNA MICROARRAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MYOEPITHELIUM CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STATISTICAL SIGNIFICANCE; ULTRASOUND;

EID: 34548450785     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/PCR.0b013e31812567b4     Document Type: Review

References (125)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence - SEER 17 Regs Public-Use, Nov 2005 Sub (1973-2003 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
2. Zujewski J, Liu ET. The 1998 St. Gallen's consensus conference: an assessment. J Natl Cancer Inst. 1998;90:1587-1589.
3. Fisher B, Jeong JH, Bryant J, et al; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymphnode-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364:858-868.
4. Goldhirsch A, Glick JH, Gelber RD, et al; Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569-1583.
5. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357-3365.
6. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93:979-989.
7. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681-1692.
8. Pease AC, Solas D, Sullivan EJ, et al. Generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci USA. 1994;91:5022-5026.
9. Lipshutz RJ, Morris D, Chee M, et al. Using oligonucleotide probe arrays to access genetic diversity. Biotechniques. 1995;19:442-447.
10. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467-470.
11. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med. 2006;354:2463-2472.
12. US Food and Drug Administration. http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01555. html. Accessed April 20, 2007.
13. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 2003;5:57-58.
14. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
15. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
16. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
17. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
18. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560-569.
19. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
20. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
21. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
22. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006 17;8:R34.
23. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-10398.
24. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA. 2001;98:11462-11467.
25. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
26. Perreard L, Fan C, Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006;8:R23.
27. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
28. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25:2273-2284.
29. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
30. Altmannsberger M, Dirk T, Droese M, et al. Keratin polypeptide distribution in benign and malignant breast tumors: subdivision of ductal carcinomas using monoclonal antibodies. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;51:265-275.
31. Wetzels RH, Kuijpers HJ, Lane EB, et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol. 1991;138:751-763.
32. Wetzels RH, Holland R, van Haelst UJ, et al. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am J Pathol. 1989;134:571-579.
33. Gould VE, Koukoulis GK, Jansson DS, et al. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast. Am J Pathol. 1990;137:1143-1155.
34. Jarasch ED, Nagle RB, Kaufmann M, et al. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol. 1988;19:276-289.
35. Guelstein VI, Tchypysheva TA, Ermilova VD, et al. Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int J Cancer. 1988;42:147-153.
36. Dairkee SH, Ljung BM, Smith H, et al. Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat. 1987;10:11-20.
37. Tsubura A, Okada H, Senzaki H, et al. Keratin expression in the normal breast and in breast carcinoma. Histopathology. 1991;18:517-522.
38. Dairkee SH, Puett L, Hackett AJ. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst. 1988;80:691-695.
39. Dairkee SH, Mayall BH, Smith HS, et al. Monoclonal marker that predicts early recurrence of breast cancer. Lancet. 1987;1:514.
40. Heatley M, Maxwell P, Whiteside C, et al. Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol. 1995;48:26-32.
41. Santini D, Ceccarelli C, Taffurelli M, et al. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol. 1996;179:386-391.
42. Domagala W, Lasota J, Bartkowiak J, et al. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol. 1990;136:219-227.
43. Domagala W, Lasota J, Dukowicz A, et al. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol. 1990;137:1299-1304.
44. Domagala W, Wozniak L, Lasota J, et al. Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas. Am J Pathol. 1990;137:1059-1064.
45. Malzahn K, Mitze M, Thoenes M, et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998;433:119-129.
46. Wellings SR, Roberts P. Electron microscopy of sclerosing adenosis and infiltrating duct carcinoma of the human mammary gland. J Natl Cancer Inst. 1963;30:269-287.
47. Murad TM. A proposed histochemical and electron microscopic classification of human breast cancer according to cell of origin. Cancer. 1971;27:288-299.
48. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004 15;10:5367-5374.
49. Li H, Cherukuri P, Li N, et al. Nestin is expressed in the basal/ myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res. 2007;67:501-510.
50. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen receptor negative breast cancers. Breast Cancer Res. 2007;9:R16.
51. Ribeiro-Silva A, Ramalho LN, Garcia SB, et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology. 2005;47:458-466.
52. Jacquemier J, Padovani L, Rabayrol L, et al; European Working Group for Breast Screening Pathology; Breast Cancer Linkage Consortium. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207:260-268.
53. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol. 2004;17:646-652.
54. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64:830-835.
55. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340-350.
56. Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res. 2004;10:5988-5997.
57. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485.
58. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007;16:104-107.
59. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495-506.
60. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729-735.
61. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37:1217-1226.
62. Kusinska R, Potemski P, Jesionek-Kupnicka D, et al. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma - relation with grade, stage, estrogen receptor and HER2. Pol J Pathol. 2005;56:107-110.
63. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. In press.
64. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006;12:1533-1539.
65. Ribeiro-Silva A, Ribeiro do Vale F, Zucoloto S. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am J Clin Pathol. 2006;125:512-518.
66. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-1996.
67. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671.
68. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10-21.
69. Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005;69:478-485.
70. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-5685.
71. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175-5180.
72. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005;18:1321-1328.
73. Reis-Filho JS, Steele D, Di Palma S, et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol. 2006;19:307-319.
74. Rodriguez-Pinilla SM, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat. 2006;99:85-90.
75. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005;11:4003-4011.
76. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22-34.
77. Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688-694.
78. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
79. Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42:3149-3156.
80. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
81. Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev. 2005;14:1108-1112.
82. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol. 2007;31:501-508.
83. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007;16:439-443.
84. Paredes J, Albergaria A, Oliveira JT, et al. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res. 2005;11:5869-5877.
85. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006;30:1097-1104.
86. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol. 2007;20:474-481.
87. Garcia S, Dales JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. In press.
88. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007;13:90-101.
89. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R4.
90. Rakha EA, El-Sayed ME, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology. 2007;50:434-438.
91. Hannemann J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 2006;95:1334-1341.
92. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002;110:633-641.
93. Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/ stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol. 2003;11:1-8.
94. Moyano JV, Evans JR, Chen F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest. 2006;116:261-270.
95. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846-5853.
96. Tsuda H, Takarabe T, Hasegawa T, et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol. 1999;10:1134-1139.
97. Tsuda H, Takarabe T, Hasegawa F, et al. Large, central acellular zones indicating myoepithelial tumor differentiaton in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol. 2000;24:197-202.
98. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40:1365-1385.
99. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66:4636-4644.
100. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology. 2000;37:175-181.
101. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basallike carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24.
102. He W, Marinescu L, Cartun RW, et al. Where were basal-like mammary duct carcinoma (BL-MDC) hiding prior to the year 2000? [abstract 140]. The 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, CA, March 24, 2007.
103. Hungermann D, Buerger H, Oehlschlegel C, et al. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast - a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells. BMC Cancer. 2005;5:92.
104. Coyne JD, Dervan PA, Barr L. High-grade carcinomas of the breast showing patterns of mixed ductal and myoepithelial differentiation (including myoepithelial cell-rich carcinoma of the breast). Histopathology. 2004;44:580-584.
105. Crisi GM, Marconi SA, Makari-Judson G, et al. Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol. 2005;124:733-739.
106. Azoulay S, Lae M, Freneaux P, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 2005;18:1623-1631.
107. Mastropasqua MG, Maiorano E, Pruneri G, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol. 2005;18:1277-1282.
108. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol. In press.
109. Ellis IO, Schnitt SJ, Sastre-Garau X Invasive breast carcinoma. In: Tavassoli FA, Devilee P (Eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:13-59.
110. Grenier J, Soria JC, Mathieu MC, et al. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res. 2007;27:547-555.
111. Leibl S, Gogg-Kammerer M, Sommersacher A, et al. Metaplastic breast carcinomas: are they of myoepithelial differentiation? Immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol. 2005;29:347-353.
112. Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol. 2005;58:700-704.
113. Bossuyt V, Fadare O, Martel M, et al. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol. 2005;13:319-327.
114. Dunne B, Lee AH, Pinder SE, et al. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol. 2003;34:1009-1015.
115. Carter MR, Hornick JL, Lester S, et al. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006;30:300-309.
116. Tse GM, Tan PH, Chaiwun B, et al. p63 is useful in the diagnosis of mammary metaplastic carcinomas. Pathology. 2006;38:16-20.
117. Barnes PJ, Boutilier R, Chiasson D, et al. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat. 2005;91:173-178.
118. Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle. 2006;5:963-967.
119. Seewaldt VL, Scott V. Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med. 2007;356:e12.
120. Albiges L, Andre F, Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005;16:1846-1847.
121. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-2334.
122. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13:1198-1207.
123. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. In press.
124. Diallo-Danebrock R, Ting E, Gluz O, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res. 2007;13:488-497.
125. Lyman GH, Cosler LE, Kuderer NM, et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007;109:1011-1018.